New combo therapy shows promise for tough pancreatic cancer
Disease control
Completed
This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine (a drug that affects gene activity), in people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could help control the …
Phase: PHASE2 • Sponsor: Susan E. Bates • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC